Results 181 to 190 of about 530,731 (290)

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma. [PDF]

Blood Cancer J
Shah MR, Bag A, Shrestha A, Ogunsesan Y, Trikannad A, Vellanki S, Muttineni S, Cheema H, Naqvi S, Dronavalli S, Al Hadidi S, Thanendrarjan S, Zangari M, van Rhee F, Szabo A, Chakraborty R, Mohan M, Schinke C.   +17 more
europepmc   +1 more source

The Haemophilia Health Journey: Experiences and Unmet Care Needs of Caregivers and Their Young Children

Haemophilia, EarlyView.
ABSTRACT Introduction Understanding patients’ and caregivers’ experiences, values and needs is essential to implement patient‐centred care. However, specific insights into how young children with haemophilia and their caregivers experience the entire care trajectory, from diagnosis onwards, remain limited.
Caroline M. A. Mussert, Eva K. Kempers, Evelien S. van Hoorn, Ekin Kerimoğlu, Marijke Melles, Mathieu A. Gielen, Armaĝan Albayrak, Kees T. B. Ahaus, Simone H. Reitsma, Samantha C. Gouw, Marjon H. Cnossen, the PARTITURA study group and SYMPHONY consortium   +11 more
wiley   +1 more source

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. [PDF]

J Immunother Cancer
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J.   +26 more
europepmc   +1 more source

Real‐World Experience With Emicizumab for Haemophilia A From the Physician Perspective in a Real‐World Clinical Setting

Haemophilia, EarlyView.
ABSTRACT Introduction Emicizumab is a bispecific antibody approved for prophylaxis in people with haemophilia A (PwHA). Aim To describe from the physician perspective the characteristics and treatment experiences of PwHA receiving emicizumab. Methods The Adelphi Real World Haemophilia Disease Specific Programme is a cross‐sectional, retrospective data ...
Michael Recht, Chris Blazos, Sophie Lai, Nathan Ball, Ella Morton, Lucy Lee, Juliana M. L. Biondo, Janet S. Lee   +7 more
wiley   +1 more source

Vaccination during bispecific antibody treatment for myeloma. [PDF]

Blood Adv
Banerjee R, Raje NS.
europepmc   +1 more source

Changes in Hypertrophic Synovium Status in Adult Patients With Severe Hemophilia A Receiving Emicizumab Prophylaxis: The RESOLVE Study

Haemophilia, EarlyView.
ABSTRACT Background Evidence on the impact of emicizumab on joint health, particularly hypertrophic synovium (HS), remains limited. Objectives To evaluate changes in HS, using point‐of‐care ultrasound and clinical examination in People with Haemophilia (PwH) switching from replacement therapy to emicizumab.
Matteo Nicola Dario Di Minno, Erminia Baldacci, Ilenia Lorenza Calcaterra, Guido D'Errico, Cristina Santoro, Alessandra Strangio, Silvia Sorella, Marzia Leotta, Rita Carlotta Santoro   +8 more
wiley   +1 more source

Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma. [PDF]

Hemasphere
Vega G, Morillo D, Riedhammer C, Smits F, Bag A, Julian K, Gomis NT, Gaisan CM, Bermudez MA, Shah MR, Mohyuddin GR, Dhakal B, Rasche L, Schinke C, D'Souza A, Szabo A, van de Donk NWCJ, Chakraborty R, Mohan M.   +18 more
europepmc   +1 more source

Patient Perspectives in Haemophilia A: Unmet Needs of Individuals Receiving Factor and Non‐Factor Treatments

Haemophilia, EarlyView.
ABSTRACT Introduction There is limited qualitative published real‐world data on treatment patterns among people with severe haemophilia A (PwSHA), particularly those with unmet needs. Aim This qualitative study aimed to explore the impact of taking prophylactic extended half‐life factor VIII (EHL‐FVIII) or emicizumab on psychosocial and physical ...
Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez‐Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis   +7 more
wiley   +1 more source

Systematic characterization of lysine glucuronidation in a bispecific antibody. [PDF]

MAbs
Reyda MR, Ji Q, Huang M, Sokolowska I, Yan Q, Mulholland J, Mo J, Hu P.   +7 more
europepmc   +1 more source

Comparison of intestinal histopathological changes following teclistamab, BCMA‐directed CAR T, CD19‐directed CAR T and rituximab therapies

Histopathology, EarlyView.
This is a retrospective review of intestinal tract biopsies from patients treated with various cellular immunotherapies (BCMA and CD19‐directed CAR T, teclistamab and rituximab therapies). We found distinct but overlapping histologic patterns across treatment groups, with lamina propria plasma cell depletion, crypt apoptotic bodies and active ...
Olivia J Leung, Esther Baranov, Isairis Peralta Valerio, Robin Collingwood, Natalie Respond, Don Siegel, Pooja Devi, Kristen M. Stashek   +7 more
wiley   +1 more source